MON2

Across TCGA pan-cancer cohorts, MON2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MON2 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MON2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MON2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where MON2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.477	0.898	.003	25	view →
HNSC	DFS	Tertile	All	0.326	0.947	.014	16	view →
LUAD	OS	Tertile	III,IV	0.925	0.327	.002	13	view →
GBM	DFS	Median	All	0.255	0.481	.014	2	view →
LSCC	OS	Quartile	All	1.000	0.678	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MON2–CCRCC (DFS)

Open the CCRCC breakdown →